Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

Volume: 36, Issue: 15_suppl, Pages: 3013 - 3013
Published: May 20, 2018
Abstract
3013 Background: IPI-549 is a potential first-in-class, oral, selective PI3K-γ inhibitor that in preclinical studies reprograms macrophages from an immune-suppressive to an immune-activating phenotype and can overcome resistance to checkpoint inhibitors. Methods: Ph 1/1b study IPI-549-01 (NCT02637531) is evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunomodulatory activity of IPI-549 to determine its...
Paper Details
Title
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
Published Date
May 20, 2018
Volume
36
Issue
15_suppl
Pages
3013 - 3013
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.